Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	peptide lactyltransferase (CoA-dependent) activity	CREBBP EP300	6.40e-06	2	51	2	GO:0120300
GeneOntologyMolecularFunction	histone H3K27 acetyltransferase activity	CREBBP EP300	6.40e-06	2	51	2	GO:0044017
GeneOntologyMolecularFunction	nuclear glucocorticoid receptor binding	NCOA2 NCOA6 EP300	1.74e-05	20	51	3	GO:0035259
GeneOntologyMolecularFunction	histone H3K18 acetyltransferase activity	CREBBP EP300	1.92e-05	3	51	2	GO:0043993
GeneOntologyMolecularFunction	peroxisome proliferator activated receptor binding	NCOA6 CREBBP EP300	2.02e-05	21	51	3	GO:0042975
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR2 RYR3	3.82e-05	4	51	2	GO:0005219
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR2 RYR3	9.53e-05	6	51	2	GO:0048763
GeneOntologyMolecularFunction	histone H3 acetyltransferase activity	CREBBP EP300	6.57e-04	15	51	2	GO:0010484
GeneOntologyMolecularFunction	intracellularly gated calcium channel activity	RYR2 RYR3	9.53e-04	18	51	2	GO:0015278
GeneOntologyMolecularFunction	transcription coactivator activity	NCOA2 NCOA6 BCL9 CREBBP EP300	1.03e-03	303	51	5	GO:0003713
GeneOntologyMolecularFunction	ankyrin binding	SPTBN4 CLTC	1.56e-03	23	51	2	GO:0030506
GeneOntologyMolecularFunction	nuclear retinoid X receptor binding	NCOA2 NCOA6	1.56e-03	23	51	2	GO:0046965
GeneOntologyMolecularFunction	molecular adaptor activity	NCOA2 SPTBN4 NCOA6 IGF2BP3 UBQLN2 GIGYF2 BCL9 SSX5 CREBBP EP300	1.99e-03	1356	51	10	GO:0060090
GeneOntologyMolecularFunction	RNA polymerase II general transcription initiation factor binding	GTF2A1 CREBBP	2.16e-03	27	51	2	GO:0001091
GeneOntologyMolecularFunction	protein-macromolecule adaptor activity	NCOA2 SPTBN4 NCOA6 IGF2BP3 UBQLN2 BCL9 SSX5 CREBBP EP300	2.44e-03	1160	51	9	GO:0030674
GeneOntologyMolecularFunction	calmodulin binding	UBR4 ASPM RYR2 RYR3	2.80e-03	230	51	4	GO:0005516
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	RYR2 RYR3	2.84e-03	31	51	2	GO:0099604
GeneOntologyMolecularFunction	transcription coregulator activity	NCOA2 NCOA6 BCL9 SSX5 CREBBP EP300	2.98e-03	562	51	6	GO:0003712
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	RYR2 RYR3	3.21e-03	33	51	2	GO:0005217
GeneOntologyMolecularFunction	nuclear thyroid hormone receptor binding	NCOA2 NCOA6	3.41e-03	34	51	2	GO:0046966
GeneOntologyMolecularFunction	bHLH transcription factor binding	CREBBP EP300	4.02e-03	37	51	2	GO:0043425
GeneOntologyMolecularFunction	RNA polymerase II-specific DNA-binding transcription factor binding	NCOA2 GTF2A1 NCOA6 CREBBP EP300	4.14e-03	417	51	5	GO:0061629
GeneOntologyMolecularFunction	disordered domain specific binding	CLTC CREBBP	4.46e-03	39	51	2	GO:0097718
HumanPheno	Abnormal facial expression	SCYL2 SPTBN4 CLTC GIGYF2 DUX4 CREBBP EP300	1.11e-05	185	23	7	HP:0005346
HumanPheno	Plantar crease between first and second toes	CREBBP EP300	1.95e-05	2	23	2	HP:0008107
HumanPheno	Aortic isthmus hypoplasia	CREBBP EP300	1.95e-05	2	23	2	HP:0034227
HumanPheno	High axial triradius	CREBBP EP300	1.95e-05	2	23	2	HP:0001042
HumanPheno	Square face	CHD7 CREBBP EP300	4.33e-05	16	23	3	HP:0000321
HumanPheno	Laryngeal cartilage malformation	CREBBP EP300	5.84e-05	3	23	2	HP:0008752
HumanPheno	Phobia	CREBBP EP300	5.84e-05	3	23	2	HP:5200232
HumanPheno	Agoraphobia	CREBBP EP300	5.84e-05	3	23	2	HP:0000756
HumanPheno	Humoral immunodeficiency	CREBBP EP300	5.84e-05	3	23	2	HP:0005363
HumanPheno	Prominent nasal septum	CREBBP EP300	5.84e-05	3	23	2	HP:0005322
HumanPheno	Radial deviation of thumb terminal phalanx	CREBBP EP300	5.84e-05	3	23	2	HP:0005895
HumanPheno	Prominent forehead	SCYL2 NEXMIF SVBP CREBBP EP300 DYNC1H1 RYR3	1.03e-04	261	23	7	HP:0011220
HumanPheno	Abnormality of facial musculature	SCYL2 SPTBN4 CLTC GIGYF2 CHD7 DUX4 DYNC1H1 RYR3	1.12e-04	361	23	8	HP:0000301
HumanPheno	Trichiasis	CREBBP EP300	1.16e-04	4	23	2	HP:0001128
HumanPheno	Visceral hemangioma	CREBBP EP300	1.16e-04	4	23	2	HP:0410266
HumanPheno	Talon cusp	CREBBP EP300	1.16e-04	4	23	2	HP:0011087
HumanPheno	Widened distal phalanges	CREBBP EP300	1.16e-04	4	23	2	HP:0006200
HumanPheno	Vascular ring	CREBBP EP300	1.16e-04	4	23	2	HP:0010775
HumanPheno	Hepatic hemangioma	CREBBP EP300	1.16e-04	4	23	2	HP:0031207
HumanPheno	Shawl scrotum	NEXMIF CREBBP EP300	1.73e-04	25	23	3	HP:0000049
HumanPheno	Papillary cystadenoma of the epididymis	CREBBP EP300	1.93e-04	5	23	2	HP:0009715
HumanPheno	Supernumerary cusp	CREBBP EP300	1.93e-04	5	23	2	HP:0033777
HumanPheno	Epididymal neoplasm	CREBBP EP300	1.93e-04	5	23	2	HP:0030421
HumanPheno	Self-injurious behavior	NEXMIF SVBP ASPM CHD7 CREBBP EP300	2.56e-04	210	23	6	HP:0100716
HumanPheno	Large foramen magnum	CREBBP EP300	2.89e-04	6	23	2	HP:0002700
HumanPheno	Abnormal branching pattern of the aortic arch	CHD7 CREBBP EP300	4.02e-04	33	23	3	HP:0011587
HumanPheno	Absent sperm axoneme central pair complex	FSIP2 QRICH2	4.04e-04	7	23	2	HP:0033525
HumanPheno	Deviated nasal septum	CREBBP EP300	4.04e-04	7	23	2	HP:0004411
HumanPheno	Decreased facial expression	SCYL2 SPTBN4 CLTC GIGYF2 DUX4	4.68e-04	151	23	5	HP:0004673
HumanPheno	Abnormal sperm axoneme morphology	FSIP2 QRICH2	5.37e-04	8	23	2	HP:0033524
HumanPheno	Skeletal muscle atrophy	SCYL2 SPTBN4 UBQLN2 RNF31 NEXMIF SVBP DUX4 DYNC1H1 RYR3	5.58e-04	579	23	9	HP:0003202
HumanPheno	Abnormality of skeletal muscles	SCYL2 SPTBN4 UBQLN2 RNF31 NEXMIF SVBP ZFP57 DUX4 DYNC1H1 RYR3	6.47e-04	727	23	10	HP:0040290
HumanPheno	Pilomatrixoma	CREBBP EP300	6.89e-04	9	23	2	HP:0030434
HumanPheno	Cervical cord compression	CREBBP EP300	6.89e-04	9	23	2	HP:0002341
HumanPheno	Abnormality of muscle size	SCYL2 SPTBN4 UBQLN2 RNF31 NEXMIF SVBP ZFP57 DUX4 DYNC1H1 RYR3	7.48e-04	740	23	10	HP:0030236
HumanPheno	Frontal hirsutism	CREBBP EP300	8.59e-04	10	23	2	HP:0011335
HumanPheno	Abnormal subclavian artery morphology	CREBBP EP300	1.05e-03	11	23	2	HP:0031251
MousePheno	abnormal epicardium morphology	NCOA6 EP300 RYR2	2.05e-05	17	45	3	MP:0003057
MousePheno	lethality throughout fetal growth and development, incomplete penetrance	ZFP57 CHD7 ATE1 CREBBP EP300 RYR2	5.07e-05	208	45	6	MP:0011109
MousePheno	hyperactivity	GPC1 NCOA2 SPTBN4 SLAIN2 ERICH3 NEXMIF SVBP LOXL4 CHD7 BCL9 CREBBP PCDH18 RYR3	5.43e-05	1172	45	13	MP:0001399
MousePheno	ventricle myocardium hypoplasia	NCOA6 ATE1 CREBBP EP300	7.78e-05	71	45	4	MP:0010502
MousePheno	embryonic growth arrest	TLN1 UBR4 DIDO1 CHD7 ATE1 CREBBP EP300	1.08e-04	346	45	7	MP:0001730
MousePheno	thin myocardium	NCOA6 CHD7 ATE1 EP300	1.57e-04	85	45	4	MP:0002652
MousePheno	lethality during fetal growth through weaning, incomplete penetrance	SCYL2 GTF2A1 NCOA6 DSG3 AMOTL1 ZFP57 GIGYF2 CHD7 ATE1 CREBBP EP300 RYR2	1.63e-04	1124	45	12	MP:0011112
MousePheno	myocardium hypoplasia	NCOA6 ATE1 CREBBP EP300	1.64e-04	86	45	4	MP:0010500
Domain	Nuc_rcpt_coact	NCOA2 CREBBP EP300	3.59e-07	6	50	3	IPR009110
Domain	Nuc_rcpt_coact_CREBbp	CREBBP EP300	7.02e-06	2	50	2	IPR014744
Domain	HAT_KAT11	CREBBP EP300	7.02e-06	2	50	2	PF08214
Domain	KIX	CREBBP EP300	7.02e-06	2	50	2	PS50952
Domain	ZnF_TAZ	CREBBP EP300	7.02e-06	2	50	2	SM00551
Domain	CBP_P300_HAT	CREBBP EP300	7.02e-06	2	50	2	IPR031162
Domain	DUF902	CREBBP EP300	7.02e-06	2	50	2	PF06001
Domain	-	CREBBP EP300	7.02e-06	2	50	2	1.20.1020.10
Domain	RING_CBP-p300	CREBBP EP300	7.02e-06	2	50	2	IPR010303
Domain	-	CREBBP EP300	7.02e-06	2	50	2	1.10.1630.10
Domain	Creb_binding	CREBBP EP300	7.02e-06	2	50	2	PF09030
Domain	-	CREBBP EP300	7.02e-06	2	50	2	1.10.246.20
Domain	zf-TAZ	CREBBP EP300	7.02e-06	2	50	2	PF02135
Domain	ZF_TAZ	CREBBP EP300	7.02e-06	2	50	2	PS50134
Domain	Histone_AcTrfase_Rtt109/CBP	CREBBP EP300	7.02e-06	2	50	2	IPR013178
Domain	KAT11	CREBBP EP300	7.02e-06	2	50	2	SM01250
Domain	Znf_TAZ	CREBBP EP300	7.02e-06	2	50	2	IPR000197
Domain	KIX_dom	CREBBP EP300	7.02e-06	2	50	2	IPR003101
Domain	KIX	CREBBP EP300	7.02e-06	2	50	2	PF02172
Domain	CBP_P300_HAT	CREBBP EP300	7.02e-06	2	50	2	PS51727
Domain	Ryanrecept_TM4-6	RYR2 RYR3	2.10e-05	3	50	2	IPR009460
Domain	RyR	RYR2 RYR3	2.10e-05	3	50	2	PF02026
Domain	Ryanodine_rcpt	RYR2 RYR3	2.10e-05	3	50	2	IPR003032
Domain	RR_TM4-6	RYR2 RYR3	2.10e-05	3	50	2	PF06459
Domain	Ryan_recept	RYR2 RYR3	2.10e-05	3	50	2	IPR013333
Domain	ARM-type_fold	SCYL2 UBQLN2 UBR4 CLTC ASPM KPNA6 RYR3	3.12e-05	339	50	7	IPR016024
Domain	RIH_assoc	RYR2 RYR3	1.05e-04	6	50	2	PF08454
Domain	RIH_assoc-dom	RYR2 RYR3	1.05e-04	6	50	2	IPR013662
Domain	RIH_dom	RYR2 RYR3	1.05e-04	6	50	2	IPR000699
Domain	Ins145_P3_rcpt	RYR2 RYR3	1.05e-04	6	50	2	IPR014821
Domain	Ryanodine_recept-rel	RYR2 RYR3	1.05e-04	6	50	2	IPR015925
Domain	-	RYR2 RYR3	1.05e-04	6	50	2	1.25.10.30
Domain	RYDR_ITPR	RYR2 RYR3	1.05e-04	6	50	2	PF01365
Domain	Ins145_P3_rec	RYR2 RYR3	1.05e-04	6	50	2	PF08709
Domain	MIR	RYR2 RYR3	3.12e-04	10	50	2	PS50919
Domain	MIR	RYR2 RYR3	3.12e-04	10	50	2	PF02815
Domain	MIR	RYR2 RYR3	3.12e-04	10	50	2	SM00472
Domain	MIR_motif	RYR2 RYR3	3.12e-04	10	50	2	IPR016093
Domain	ZZ	CREBBP EP300	1.05e-03	18	50	2	PF00569
Domain	ZF_ZZ_2	CREBBP EP300	1.05e-03	18	50	2	PS50135
Domain	ZF_ZZ_1	CREBBP EP300	1.05e-03	18	50	2	PS01357
Domain	Znf_ZZ	CREBBP EP300	1.17e-03	19	50	2	IPR000433
Domain	ZnF_ZZ	CREBBP EP300	1.17e-03	19	50	2	SM00291
Domain	Bromodomain_CS	CREBBP EP300	2.19e-03	26	50	2	IPR018359
Domain	UBA	UBQLN2 RNF31	4.18e-03	36	50	2	PF00627
Domain	BROMODOMAIN_1	CREBBP EP300	4.41e-03	37	50	2	PS00633
Domain	Bromodomain	CREBBP EP300	4.64e-03	38	50	2	PF00439
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	NCOA2 NCOA6 CREBBP EP300	1.20e-07	18	37	4	M26942
Pathway	REACTOME_HEME_SIGNALING	NCOA2 NCOA6 USP46 CREBBP EP300	1.65e-07	49	37	5	M41832
Pathway	REACTOME_CIRCADIAN_CLOCK	NCOA2 NCOA6 USP46 CREBBP EP300	1.01e-06	70	37	5	M938
Pathway	REACTOME_ADIPOGENESIS	NCOA2 NCOA6 USP46 CREBBP EP300	9.43e-06	110	37	5	M48259
Pathway	REACTOME_ZYGOTIC_GENOME_ACTIVATION_ZGA	DUX4 CREBBP EP300	1.10e-05	17	37	3	M48025
Pathway	REACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS	NCOA2 NCOA6 USP46 CREBBP	1.24e-05	55	37	4	M27145
Pathway	REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA	NCOA2 NCOA6 CREBBP EP300 TIAM2	1.33e-05	118	37	5	M27316
Pathway	BIOCARTA_CARM_ER_PATHWAY	GTF2A1 CREBBP EP300	4.15e-05	26	37	3	M2499
Pathway	REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_GENE_EXPRESSION	NCOA2 NCOA6 CREBBP	4.66e-05	27	37	3	M26943
Pathway	PID_RETINOIC_ACID_PATHWAY	NCOA2 CREBBP EP300	6.44e-05	30	37	3	M207
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION	NCOA2 NCOA6 CREBBP EP300	6.67e-05	84	37	4	M1008
Pathway	BIOCARTA_PELP1_PATHWAY	CREBBP EP300	6.67e-05	5	37	2	MM1575
Pathway	REACTOME_NFE2L2_REGULATING_INFLAMMATION_ASSOCIATED_GENES	CREBBP EP300	6.67e-05	5	37	2	M48020
Pathway	REACTOME_NFE2L2_REGULATING_ER_STRESS_ASSOCIATED_GENES	CREBBP EP300	6.67e-05	5	37	2	M48023
Pathway	REACTOME_LRR_FLII_INTERACTING_PROTEIN_1_LRRFIP1_ACTIVATES_TYPE_I_IFN_PRODUCTION	CREBBP EP300	6.67e-05	5	37	2	M27228
Pathway	BIOCARTA_PELP1_PATHWAY	CREBBP EP300	9.99e-05	6	37	2	M22062
Pathway	REACTOME_MITOCHONDRIAL_BIOGENESIS	NCOA2 NCOA6 USP46 CREBBP	1.12e-04	96	37	4	M26973
Pathway	BIOCARTA_PPARG_PATHWAY	CREBBP EP300	1.40e-04	7	37	2	MM1573
Pathway	REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP	NCOA2 NCOA6 CREBBP	1.78e-04	42	37	3	M27172
Pathway	BIOCARTA_PPARG_PATHWAY	CREBBP EP300	1.86e-04	8	37	2	M22058
Pathway	REACTOME_NFE2L2_REGULATING_MDR_ASSOCIATED_ENZYMES	CREBBP EP300	1.86e-04	8	37	2	M48022
Pathway	REACTOME_REGULATION_OF_NFE2L2_GENE_EXPRESSION	CREBBP EP300	1.86e-04	8	37	2	M48024
Pathway	REACTOME_NFE2L2_REGULATES_PENTOSE_PHOSPHATE_PATHWAY_GENES	CREBBP EP300	1.86e-04	8	37	2	M46443
Pathway	REACTOME_DEVELOPMENTAL_BIOLOGY	GPC1 NCOA2 SPTBN4 NCOA6 DSG3 TLN1 NCAN CLTC DUX4 USP46 CREBBP EP300	1.90e-04	1432	37	12	M509
Pathway	REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS	NCOA2 CREBBP EP300	2.05e-04	44	37	3	M27295
Pathway	KEGG_MEDICUS_REFERENCE_TLR3_IRF3_SIGNALING_PATHWAY	CREBBP EP300	2.39e-04	9	37	2	M47451
Pathway	REACTOME_REGULATION_OF_FOXO_TRANSCRIPTIONAL_ACTIVITY_BY_ACETYLATION	CREBBP EP300	2.98e-04	10	37	2	M27945
Pathway	PID_AR_TF_PATHWAY	NCOA2 CREBBP EP300	3.56e-04	53	37	3	M151
Pathway	BIOCARTA_CARM1_PATHWAY	CREBBP EP300	3.63e-04	11	37	2	MM1521
Pathway	REACTOME_NFE2L2_REGULATING_TUMORIGENIC_GENES	CREBBP EP300	3.63e-04	11	37	2	M48021
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_BY_HYPOXIA_INDUCIBLE_FACTOR	CREBBP EP300	3.63e-04	11	37	2	M26924
Pathway	KEGG_MEDICUS_REFERENCE_CA2_CAM_VGCC_RYR_SIGNALING_PATHWAY	RYR2 RYR3	3.63e-04	11	37	2	M47958
Pathway	REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF	NCOA2 NCOA6 CREBBP	3.98e-04	55	37	3	M27001
Pathway	BIOCARTA_CARM1_PATHWAY	CREBBP EP300	4.35e-04	12	37	2	M7968
Pathway	REACTOME_ACTIVATION_OF_THE_TFAP2_AP_2_FAMILY_OF_TRANSCRIPTION_FACTORS	CREBBP EP300	4.35e-04	12	37	2	M27765
Pathway	REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM	GPC1 GLB1L3 NCAN	4.42e-04	57	37	3	M692
Pathway	WP_CELLTYPE_DEPENDENT_SELECTIVITY_OF_CCK2R_SIGNALING	RYR2 RYR3	5.13e-04	13	37	2	M39589
Pathway	REACTOME_CYTOPROTECTION_BY_HMOX1	NCOA2 NCOA6 CREBBP	5.14e-04	60	37	3	M41830
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	NCOA2 GTF2A1 EP300	5.93e-04	63	37	3	MM15613
Pathway	REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING	CREBBP EP300	5.98e-04	14	37	2	M27808
Pathway	REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION	NCOA2 GTF2A1 CREBBP EP300	6.04e-04	149	37	4	M27888
Pathway	PID_HIF1_TFPATHWAY	NCOA2 CREBBP EP300	6.80e-04	66	37	3	M255
Pathway	BIOCARTA_RELA_PATHWAY	CREBBP EP300	6.89e-04	15	37	2	MM1339
Pathway	BIOCARTA_RELA_PATHWAY	CREBBP EP300	6.89e-04	15	37	2	M10183
Pathway	BIOCARTA_PITX2_PATHWAY	CREBBP EP300	6.89e-04	15	37	2	MM1439
Pathway	REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY	CREBBP EP300	6.89e-04	15	37	2	M953
Pathway	REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS	CREBBP EP300	7.86e-04	16	37	2	M27121
Pathway	BIOCARTA_IL7_PATHWAY	CREBBP EP300	7.86e-04	16	37	2	M1296
Pathway	BIOCARTA_IL7_PATHWAY	CREBBP EP300	7.86e-04	16	37	2	MM1420
Pathway	BIOCARTA_PITX2_PATHWAY	CREBBP EP300	7.86e-04	16	37	2	M8516
Pathway	REACTOME_FOXO_MEDIATED_TRANSCRIPTION_OF_CELL_DEATH_GENES	CREBBP EP300	7.86e-04	16	37	2	M27940
Pathway	BIOCARTA_TGFB_PATHWAY	CREBBP EP300	8.89e-04	17	37	2	MM1509
Pathway	WP_PATHOPHYSIOLOGICAL_ROLES_OF_DUX4_IN_FSHD1	DUX4 EP300	9.99e-04	18	37	2	M48069
Pathway	REACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE	NCOA2 NCOA6 USP46 CREBBP DYNC1H1	1.01e-03	297	37	5	M27050
Pathway	BIOCARTA_TGFB_PATHWAY	CREBBP EP300	1.11e-03	19	37	2	M18933
Pathway	KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY	RYR2 RYR3	1.11e-03	19	37	2	M47760
Pathway	REACTOME_NFE2L2_REGULATING_ANTI_OXIDANT_DETOXIFICATION_ENZYMES	CREBBP EP300	1.11e-03	19	37	2	M46442
Pathway	PID_BETA_CATENIN_NUC_PATHWAY	NCOA2 BCL9 EP300	1.19e-03	80	37	3	M223
Pathway	REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	CREBBP EP300	1.24e-03	20	37	2	M27881
Pathway	REACTOME_DEFECTIVE_B4GALT7_CAUSES_EDS_PROGEROID_TYPE	GPC1 NCAN	1.24e-03	20	37	2	M27258
Pathway	PID_SMAD2_3NUCLEAR_PATHWAY	NCOA2 CREBBP EP300	1.28e-03	82	37	3	M2
Pathway	PID_REG_GR_PATHWAY	NCOA2 CREBBP EP300	1.28e-03	82	37	3	M115
Pathway	WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX	CREBBP EP300	1.36e-03	21	37	2	M39593
Pathway	REACTOME_CD209_DC_SIGN_SIGNALING	CREBBP EP300	1.36e-03	21	37	2	M27485
Pathway	BIOCARTA_VDR_PATHWAY	CREBBP EP300	1.50e-03	22	37	2	MM1370
Pathway	BIOCARTA_NTHI_PATHWAY	CREBBP EP300	1.50e-03	22	37	2	MM1443
Pathway	REACTOME_HS_GAG_DEGRADATION	GPC1 GLB1L3	1.64e-03	23	37	2	MM14804
Pathway	BIOCARTA_NTHI_PATHWAY	CREBBP EP300	1.64e-03	23	37	2	M2821
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	BCL9 CREBBP EP300	1.73e-03	91	37	3	M27101
Pathway	WP_ANDROGEN_RECEPTOR_SIGNALING	NCOA2 CREBBP EP300	1.73e-03	91	37	3	M39700
Pathway	BIOCARTA_VDR_PATHWAY	CREBBP EP300	1.78e-03	24	37	2	M13404
Pathway	REACTOME_HS_GAG_DEGRADATION	GPC1 GLB1L3	1.78e-03	24	37	2	M636
Pathway	REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION	CREBBP EP300	1.94e-03	25	37	2	M27880
Pathway	PID_HDAC_CLASSIII_PATHWAY	CREBBP EP300	2.09e-03	26	37	2	M32
Pathway	REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS	GPC1 NCAN	2.09e-03	26	37	2	M708
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	BCL9 EP300	2.09e-03	26	37	2	MM14793
Pathway	REACTOME_RSV_HOST_INTERACTIONS	GPC1 CREBBP EP300	2.13e-03	98	37	3	M48247
Pathway	REACTOME_CELLULAR_RESPONSE_TO_CHEMICAL_STRESS	NCOA2 NCOA6 CREBBP EP300	2.15e-03	210	37	4	M41836
Pathway	REACTOME_ATTENUATION_PHASE	CREBBP EP300	2.43e-03	28	37	2	M27254
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	NCOA2 GTF2A1 CREBBP EP300	2.55e-03	220	37	4	M27794
Pathway	REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION	CREBBP EP300	2.78e-03	30	37	2	M936
Pathway	WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY	NCOA2 NCOA6	2.97e-03	31	37	2	M39476
Pathway	REACTOME_METABOLISM_OF_LIPIDS	NCOA2 NCOA6 GLB1L3 BCHE CREBBP EP300 TIAM2	3.14e-03	757	37	7	M27451
Pathway	WP_INITIATION_OF_TRANSCRIPTION_AND_TRANSLATION_ELONGATION_AT_THE_HIV1_LTR	CREBBP EP300	3.16e-03	32	37	2	M39521
Pathway	WP_TYPE_2_PAPILLARY_RENAL_CELL_CARCINOMA	CREBBP EP300	3.57e-03	34	37	2	M39771
Pathway	PID_HIF2PATHWAY	CREBBP EP300	3.57e-03	34	37	2	M44
Pathway	REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES	CREBBP EP300	3.78e-03	35	37	2	M48246
Pathway	REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY	GPC1 CREBBP EP300	3.79e-03	120	37	3	M48233
Pathway	REACTOME_L1CAM_INTERACTIONS	SPTBN4 NCAN CLTC	3.87e-03	121	37	3	M872
Pathway	REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS	NCOA6 CREBBP EP300	3.96e-03	122	37	3	M29689
Pathway	REACTOME_GLYCOSAMINOGLYCAN_METABOLISM	GPC1 GLB1L3 NCAN	4.34e-03	126	37	3	M695
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_THE_AP_2_TFAP2_FAMILY_OF_TRANSCRIPTION_FACTORS	CREBBP EP300	4.44e-03	38	37	2	M27757
Pathway	REACTOME_HSF1_DEPENDENT_TRANSACTIVATION	CREBBP EP300	4.44e-03	38	37	2	M27255
Pathway	REACTOME_MATERNAL_TO_ZYGOTIC_TRANSITION_MZT	DUX4 CREBBP EP300	4.54e-03	128	37	3	M48019
Pathway	WP_EBOLA_VIRUS_INFECTION_IN_HOST	CLTC CREBBP EP300	4.64e-03	129	37	3	M39693
Pathway	REACTOME_NERVOUS_SYSTEM_DEVELOPMENT	GPC1 SPTBN4 TLN1 CLTC	4.69e-03	261	37	4	MM15676
Pathway	PID_FOXM1_PATHWAY	CREBBP EP300	4.91e-03	40	37	2	M176
Pathway	PID_IFNG_PATHWAY	CREBBP EP300	4.91e-03	40	37	2	M161
Pathway	REACTOME_ESR_MEDIATED_SIGNALING	NCOA2 GTF2A1 EP300	5.05e-03	133	37	3	MM15529
Pathway	REACTOME_CELLULAR_RESPONSES_TO_STIMULI	NCOA2 NCOA6 TLN1 USP46 CREBBP EP300 DYNC1H1	5.15e-03	828	37	7	M27827
Pubmed	The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	4.13e-16	8	57	6	17588759
Pubmed	DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	3.09e-15	10	57	6	17984056
Pubmed	Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	1.35e-14	12	57	6	10433963
Pubmed	Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	2.51e-14	13	57	6	17668377
Pubmed	Characterization of a tandemly repeated 3.3-kb KpnI unit in the facioscapulohumeral muscular dystrophy (FSHD) gene region on chromosome 4q35.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	2.51e-14	13	57	6	7739628
Pubmed	Active genes in junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements.	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	1.80e-13	17	57	6	11245978
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	SCYL2 NCOA2 SLAIN2 NCOA6 TLN1 AMOTL1 CLTC GIGYF2 DIDO1 CREBBP EP300 DYNC1H1	7.88e-11	549	57	12	38280479
Pubmed	DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes.	DUX4 CREBBP EP300	4.17e-09	3	57	3	26951377
Pubmed	Acetylation of importin-alpha nuclear import factors by CBP/p300.	KPNA6 CREBBP EP300	1.67e-08	4	57	3	10801418
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	NCOA2 SLAIN2 NCOA6 IGF2BP3 TLN1 CLTC DIDO1 CHD7 BCL9 LSM7 CREBBP EP300 DYNC1H1	2.05e-08	1103	57	13	34189442
Pubmed	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.	NCOA2 NCOA6 CREBBP EP300	3.08e-08	20	57	4	11877444
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA2 NCOA6 CREBBP EP300	3.80e-08	21	57	4	19596656
Pubmed	Interaction of PIMT with transcriptional coactivators CBP, p300, and PBP differential role in transcriptional regulation.	NCOA6 CREBBP EP300	4.16e-08	5	57	3	11912212
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	NCOA2 SPTBN4 PTPRN2 NCAN UBR4 CLTC ADGRB3 GIGYF2 DIDO1 CHD7 BCL9 DYNC1H1	4.27e-08	963	57	12	28671696
Pubmed	Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination.	NCOA2 CREBBP EP300	8.32e-08	6	57	3	15731352
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	SCYL2 NCOA2 SPTBN4 UBQLN2 UBR4 CLTC ADGRB3 KPNA6 HERPUD2 CREBBP EP300 DYNC1H1 RYR3	1.21e-07	1285	57	13	35914814
Pubmed	Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.	NCOA2 CREBBP EP300	1.45e-07	7	57	3	9590696
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	NCOA2 GTF2A1 AMOTL1 BCL9 CREBBP EP300	1.91e-07	152	57	6	38360978
Pubmed	Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.	NCOA2 CREBBP EP300	2.32e-07	8	57	3	10490106
Pubmed	Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.	NCOA2 NCOA6 CHD7 BCL9 EP300	2.60e-07	83	57	5	28794006
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	NCOA6 UBQLN2 TLN1 UBR4 CLTC CHD7 BCL9 DYNC1H1	4.98e-07	430	57	8	35044719
Pubmed	Activating signal cointegrator 1, a novel transcription coactivator of nuclear receptors, and its cytosolic localization under conditions of serum deprivation.	GTF2A1 CREBBP EP300	6.82e-07	11	57	3	10454579
Pubmed	The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1.	GTF2A1 NEXMIF TLN1 CHD7 CREBBP RYR2	8.73e-07	197	57	6	20811636
Pubmed	Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator.	NCOA6 CREBBP EP300	9.09e-07	12	57	3	12189208
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NCOA2 NCOA6 PTPRN2 UBR4 CHD7 BCL9 CREBBP EP300 RYR2	9.13e-07	638	57	9	31182584
Pubmed	Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins.	NCOA2 NCOA6 CREBBP	1.50e-06	14	57	3	12482968
Pubmed	A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo.	GTF2A1 NCOA6 CREBBP	1.87e-06	15	57	3	10567404
Pubmed	Loss of p300 accelerates MDS-associated leukemogenesis.	CREBBP EP300	2.64e-06	2	57	2	27881875
Pubmed	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.	CREBBP EP300	2.64e-06	2	57	2	34845315
Pubmed	p300 plays a critical role in maintaining cardiac mitochondrial function and cell survival in postnatal hearts.	CREBBP EP300	2.64e-06	2	57	2	19729597
Pubmed	Endogenous CCAAT/enhancer binding protein beta and p300 are both regulated by growth hormone to mediate transcriptional activation.	CREBBP EP300	2.64e-06	2	57	2	15860545
Pubmed	Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.	CREBBP EP300	2.64e-06	2	57	2	29460469
Pubmed	Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.	CREBBP EP300	2.64e-06	2	57	2	24551300
Pubmed	Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease.	RYR2 RYR3	2.64e-06	2	57	2	21531043
Pubmed	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.	CREBBP EP300	2.64e-06	2	57	2	33911074
Pubmed	The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co-activator family, including the CREB-binding protein CBP and p300.	CREBBP EP300	2.64e-06	2	57	2	9018065
Pubmed	Coactivators p300 and CBP maintain the identity of mouse embryonic stem cells by mediating long-range chromatin structure.	CREBBP EP300	2.64e-06	2	57	2	24648406
Pubmed	CBP and P300 regulate distinct gene networks required for human primary myoblast differentiation and muscle integrity.	CREBBP EP300	2.64e-06	2	57	2	30135524
Pubmed	Modulation of calcium signalling by dominant negative splice variant of ryanodine receptor subtype 3 in native smooth muscle cells.	RYR2 RYR3	2.64e-06	2	57	2	16678258
Pubmed	CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.	CREBBP EP300	2.64e-06	2	57	2	39287984
Pubmed	Distribution of co-activators CBP and p300 during mouse oocyte and embryo development.	CREBBP EP300	2.64e-06	2	57	2	16596650
Pubmed	The p300 and CBP Transcriptional Coactivators Are Required for β-Cell and α-Cell Proliferation.	CREBBP EP300	2.64e-06	2	57	2	29217654
Pubmed	Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein-Taybi syndrome detected by aCGH.	CREBBP EP300	2.64e-06	2	57	2	20717166
Pubmed	Differences in the interactions of oncogenic adenovirus 12 early region 1A and nononcogenic adenovirus 2 early region 1A with the cellular coactivators p300 and CBP.	CREBBP EP300	2.64e-06	2	57	2	10049825
Pubmed	CBP/p300 acetyltransferase activity in hematologic malignancies.	CREBBP EP300	2.64e-06	2	57	2	27380996
Pubmed	CREBBP and p300 lysine acetyl transferases in the DNA damage response.	CREBBP EP300	2.64e-06	2	57	2	29170789
Pubmed	The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.	CREBBP EP300	2.64e-06	2	57	2	25893291
Pubmed	Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.	CREBBP EP300	2.64e-06	2	57	2	11559821
Pubmed	Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis.	CREBBP EP300	2.64e-06	2	57	2	21555743
Pubmed	CBP/p300 induction is required for retinoic acid sensitivity in human mammary cells.	CREBBP EP300	2.64e-06	2	57	2	12646247
Pubmed	CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.	CREBBP EP300	2.64e-06	2	57	2	32576962
Pubmed	Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.	CREBBP EP300	2.64e-06	2	57	2	19822209
Pubmed	A specific CBP/p300-dependent gene expression programme drives the metabolic remodelling in late stages of spermatogenesis.	CREBBP EP300	2.64e-06	2	57	2	24522976
Pubmed	Histone acetyltransferase activities of cAMP-regulated enhancer-binding protein and p300 in tissues of fetal, young, and old mice.	CREBBP EP300	2.64e-06	2	57	2	11867645
Pubmed	CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement.	CREBBP EP300	2.64e-06	2	57	2	21847097
Pubmed	Tissue-specific alternative splicing of mouse brain type ryanodine receptor/calcium release channel mRNA.	RYR2 RYR3	2.64e-06	2	57	2	8898078
Pubmed	Expression of the nuclear coactivators CBP and p300 in developing craniofacial tissue.	CREBBP EP300	2.64e-06	2	57	2	11963968
Pubmed	p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes.	CREBBP EP300	2.64e-06	2	57	2	34813504
Pubmed	Differential transcriptional activation by human T-cell leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB binding protein and p300.	CREBBP EP300	2.64e-06	2	57	2	9528808
Pubmed	Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.	CREBBP EP300	2.64e-06	2	57	2	12696060
Pubmed	The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors.	RYR2 RYR3	2.64e-06	2	57	2	14550562
Pubmed	Rubinstein-Taybi Syndrome	CREBBP EP300	2.64e-06	2	57	2	20301699
Pubmed	CBP Is Required for Establishing Adaptive Gene Programs in the Adult Mouse Brain.	CREBBP EP300	2.64e-06	2	57	2	36109165
Pubmed	Potential biomarker of metformin action.	CREBBP EP300	2.64e-06	2	57	2	24639469
Pubmed	The histone acetyl transferases CBP and p300 regulate stress response pathways in synovial fibroblasts at transcriptional and functional levels.	CREBBP EP300	2.64e-06	2	57	2	37816914
Pubmed	Retinoids and retinoic acid receptors regulate growth arrest and apoptosis in human mammary epithelial cells and modulate expression of CBP/p300.	CREBBP EP300	2.64e-06	2	57	2	12242694
Pubmed	Binding of p300/CBP co-activators by polyoma large T antigen.	CREBBP EP300	2.64e-06	2	57	2	11438528
Pubmed	Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators.	CREBBP EP300	2.64e-06	2	57	2	10918613
Pubmed	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.	CREBBP EP300	2.64e-06	2	57	2	31182547
Pubmed	Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.	CREBBP EP300	2.64e-06	2	57	2	35502657
Pubmed	Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.	CREBBP EP300	2.64e-06	2	57	2	30635043
Pubmed	p300 and cAMP response element-binding protein-binding protein in skeletal muscle homeostasis, contractile function, and survival.	CREBBP EP300	2.64e-06	2	57	2	31898871
Pubmed	Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.	CREBBP EP300	2.64e-06	2	57	2	27648933
Pubmed	Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.	CREBBP EP300	2.64e-06	2	57	2	30888860
Pubmed	Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.	CREBBP EP300	2.64e-06	2	57	2	27881443
Pubmed	Spatiotemporal expression of histone acetyltransferases, p300 and CBP, in developing embryonic hearts.	CREBBP EP300	2.64e-06	2	57	2	19272189
Pubmed	Developmentally regulated expression of the transcriptional cofactors/histone acetyltransferases CBP and p300 during mouse embryogenesis.	CREBBP EP300	2.64e-06	2	57	2	10610021
Pubmed	Emerging roles of p300/CBP in autophagy and autophagy-related human disorders.	CREBBP EP300	2.64e-06	2	57	2	37314181
Pubmed	Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal.	CREBBP EP300	2.64e-06	2	57	2	12397173
Pubmed	CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding.	CREBBP EP300	2.64e-06	2	57	2	15641773
Pubmed	Differential contribution of p300 and CBP to regulatory element acetylation in mESCs.	CREBBP EP300	2.64e-06	2	57	2	32690000
Pubmed	Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein.	CREBBP EP300	2.64e-06	2	57	2	9733868
Pubmed	CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice.	CREBBP EP300	2.64e-06	2	57	2	30953353
Pubmed	Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.	CREBBP EP300	2.64e-06	2	57	2	21803292
Pubmed	HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.	CREBBP EP300	2.64e-06	2	57	2	9811832
Pubmed	Two independent regions of simian virus 40 T antigen increase CBP/p300 levels, alter patterns of cellular histone acetylation, and immortalize primary cells.	CREBBP EP300	2.64e-06	2	57	2	24089570
Pubmed	Decreased expression of ryanodine receptors alters calcium-induced calcium release mechanism in mdx duodenal myocytes.	RYR2 RYR3	2.64e-06	2	57	2	14985349
Pubmed	Rubinstein-Taybi syndrome in Chinese population with four novel mutations.	CREBBP EP300	2.64e-06	2	57	2	33063428
Pubmed	EP300/CBP is crucial for cAMP-PKA pathway to alleviate podocyte dedifferentiation via targeting Notch3 signaling.	CREBBP EP300	2.64e-06	2	57	2	34506759
Pubmed	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.	CREBBP EP300	2.64e-06	2	57	2	22177454
Pubmed	Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease.	CREBBP EP300	2.64e-06	2	57	2	15706485
Pubmed	AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.	CREBBP EP300	2.64e-06	2	57	2	39266679
Pubmed	A boy with classical Rubinstein-Taybi syndrome but no detectable mutation in the CREBBP and EP300 genes.	CREBBP EP300	2.64e-06	2	57	2	22303793
Pubmed	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.	CREBBP EP300	2.64e-06	2	57	2	34732714
Pubmed	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.	CREBBP EP300	2.64e-06	2	57	2	34019788
Pubmed	Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.	NCOA2 CREBBP EP300	2.79e-06	17	57	3	19183483
Pubmed	Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling.	NCOA6 CREBBP EP300	2.79e-06	17	57	3	28291835
Pubmed	Human transcription factor protein interaction networks.	NCOA2 NCOA6 IGF2BP3 UBR4 GIGYF2 DIDO1 CHD7 USP46 BCL9 CREBBP EP300 DYNC1H1	2.81e-06	1429	57	12	35140242
Pubmed	The PHLPP1 N-Terminal Extension Is a Mitotic Cdk1 Substrate and Controls an Interactome Switch.	TLN1 CLTC ASPM GIGYF2 DIDO1 DYNC1H1	3.97e-06	256	57	6	33397691
Pubmed	Dendrite development regulated by CREST, a calcium-regulated transcriptional activator.	CREBBP EP300	7.91e-06	3	57	2	14716005
Interaction	ERG interactions	NCOA2 NCOA6 UBR4 CLTC CHD7 BCL9 CREBBP EP300	8.38e-08	223	51	8	int:ERG
Interaction	WWTR1 interactions	SCYL2 NCOA2 SLAIN2 NCOA6 TLN1 AMOTL1 CLTC DIDO1 CREBBP EP300	8.65e-08	422	51	10	int:WWTR1
Interaction	TBXT interactions	NCOA2 NCOA6 CHD7 BCL9 CREBBP EP300	4.65e-07	116	51	6	int:TBXT
Interaction	EYA4 interactions	NCOA2 GTF2A1 UBQLN2 AMOTL1 BCL9 CREBBP EP300	2.50e-06	243	51	7	int:EYA4
Interaction	EGR2 interactions	NCOA2 NCOA6 CHD7 BCL9 CREBBP EP300	4.49e-06	171	51	6	int:EGR2
Interaction	SOX9 interactions	NCOA6 CHD7 BCL9 CREBBP EP300	4.59e-06	97	51	5	int:SOX9
Interaction	TLX1 interactions	NCOA2 IGF2BP3 CHD7 BCL9 CREBBP EP300	5.13e-06	175	51	6	int:TLX1
Interaction	EID1 interactions	NCOA2 ASPM CREBBP EP300	8.33e-06	51	51	4	int:EID1
Interaction	PAX8 interactions	NCOA2 CHD7 BCL9 CREBBP EP300	8.89e-06	111	51	5	int:PAX8
Interaction	CEBPA interactions	NCOA2 SLAIN2 NCOA6 IGF2BP3 TLN1 CLTC DIDO1 CHD7 BCL9 LSM7 CREBBP EP300 DYNC1H1	9.40e-06	1245	51	13	int:CEBPA
Interaction	SP7 interactions	NCOA2 NCOA6 IGF2BP3 CHD7 BCL9 CREBBP EP300	1.09e-05	304	51	7	int:SP7
Interaction	FEV interactions	NCOA2 NCOA6 CHD7 BCL9 CREBBP EP300	1.20e-05	203	51	6	int:FEV
Interaction	TRAFD1 interactions	UBQLN2 RNF31 CLTC ASPM	1.60e-05	60	51	4	int:TRAFD1
Interaction	DUX4 interactions	IGF2BP3 CLTC DUX4 CREBBP EP300 DYNC1H1	1.62e-05	214	51	6	int:DUX4
Interaction	XRCC6 interactions	GTF2A1 NCOA6 IGF2BP3 UBQLN2 RNF31 CLTC DIDO1 CHD7 DUX4 CREBBP EP300	1.63e-05	928	51	11	int:XRCC6
Interaction	PAX9 interactions	NCOA2 NCOA6 CHD7 BCL9 EP300	1.91e-05	130	51	5	int:PAX9
Interaction	PHLPP1 interactions	TLN1 CLTC ASPM GIGYF2 DIDO1 USP46 DYNC1H1	1.96e-05	333	51	7	int:PHLPP1
Interaction	ETV4 interactions	NCOA2 BCL9 CREBBP EP300	2.79e-05	69	51	4	int:ETV4
Interaction	CNTN2 interactions	NCAN CREBBP EP300	2.98e-05	24	51	3	int:CNTN2
Interaction	NCOA6 interactions	NCOA2 GTF2A1 NCOA6 CREBBP EP300	3.24e-05	145	51	5	int:NCOA6
Interaction	HNF1A interactions	GTF2A1 CREBBP EP300 RYR3	4.99e-05	80	51	4	int:HNF1A
Interaction	SOX7 interactions	NCOA2 CHD7 CREBBP EP300	5.50e-05	82	51	4	int:SOX7
Interaction	FMR1 interactions	NCOA2 IGF2BP3 PTPRN2 UBR4 GIGYF2 CHD7 BCL9 DYNC1H1	5.53e-05	536	51	8	int:FMR1
Interaction	SPATA1 interactions	SCYL2 UBR4 EP300	6.53e-05	31	51	3	int:SPATA1
Interaction	ITGB3 interactions	UBQLN2 TLN1 UBR4 CLTC DYNC1H1	6.91e-05	170	51	5	int:ITGB3
Interaction	CREM interactions	UBQLN2 UBR4 CREBBP DYNC1H1	7.92e-05	90	51	4	int:CREM
Interaction	SOX10 interactions	NCOA2 CHD7 BCL9 EP300	8.62e-05	92	51	4	int:SOX10
Interaction	TAL1 interactions	UBR4 CREBBP EP300 DYNC1H1	9.00e-05	93	51	4	int:TAL1
Interaction	SOX17 interactions	NCOA2 NCOA6 CHD7 BCL9	9.77e-05	95	51	4	int:SOX17
Interaction	THRB interactions	NCOA2 NCOA6 PTPRN2 CHD7 EP300	1.06e-04	186	51	5	int:THRB
Interaction	HNF1B interactions	NCOA2 CHD7 BCL9 CREBBP EP300	1.17e-04	190	51	5	int:HNF1B
Interaction	IRF7 interactions	RNF31 CREBBP EP300 DYNC1H1	1.19e-04	100	51	4	int:IRF7
Interaction	PPARG interactions	NCOA2 NCOA6 TLN1 GIGYF2 CREBBP EP300	1.20e-04	307	51	6	int:PPARG
Interaction	RORA interactions	NCOA2 CREBBP EP300	1.31e-04	39	51	3	int:RORA
Interaction	KLF5 interactions	NCOA2 NCOA6 BCL9 CREBBP EP300	1.32e-04	195	51	5	int:KLF5
Interaction	GATA2 interactions	NCOA6 CHD7 BCL9 CREBBP EP300	1.45e-04	199	51	5	int:GATA2
Interaction	BAG2 interactions	SCYL2 NCOA2 NCOA6 RNF31 TLN1 CLTC CREBBP EP300	1.55e-04	622	51	8	int:BAG2
Interaction	AR interactions	NCOA2 NCOA6 RNF31 CLTC DIDO1 CHD7 BCL9 CREBBP EP300 DYNC1H1	1.62e-04	992	51	10	int:AR
Interaction	CLINT1 interactions	SCYL2 UBQLN2 RNF31 CLTC EP300	1.74e-04	207	51	5	int:CLINT1
Interaction	THRA interactions	NCOA2 NCOA6 CREBBP EP300	1.78e-04	111	51	4	int:THRA
Interaction	CTNNB1 interactions	GPC1 NCOA2 TLN1 AMOTL1 ASPM DUX4 BCL9 CREBBP EP300 DYNC1H1	1.86e-04	1009	51	10	int:CTNNB1
Interaction	TBR1 interactions	NCOA2 CHD7 BCL9 EP300	1.91e-04	113	51	4	int:TBR1
Interaction	RNF123 interactions	IGF2BP3 UBQLN2 PTPRN2 NEXMIF TLN1 UBR4 CLTC QRICH2 DYNC1H1	1.99e-04	824	51	9	int:RNF123
Interaction	TERF2 interactions	GTF2A1 NEXMIF TLN1 CHD7 EP300 RYR2	2.10e-04	340	51	6	int:TERF2
Interaction	HMGB1 interactions	GTF2A1 NCAN CLTC KPNA6 DUX4 CREBBP EP300	2.10e-04	486	51	7	int:HMGB1
Interaction	HOXB3 interactions	CREBBP EP300	2.23e-04	9	51	2	int:HOXB3
Interaction	ARGFX interactions	CREBBP EP300	2.23e-04	9	51	2	int:ARGFX
Interaction	BMI1 interactions	IGF2BP3 CLTC GIGYF2 DIDO1 CREBBP EP300 DYNC1H1 RYR3	2.30e-04	659	51	8	int:BMI1
Interaction	NR1I2 interactions	NCOA2 NCOA6 EP300	2.44e-04	48	51	3	int:NR1I2
Interaction	RAD23A interactions	UBQLN2 UBR4 LOXL4 CREBBP EP300	2.51e-04	224	51	5	int:RAD23A
Interaction	PAX7 interactions	CHD7 BCL9 CREBBP EP300	2.73e-04	124	51	4	int:PAX7
Interaction	RPS20 interactions	GPC1 IGF2BP3 RNF31 GIGYF2 DUX4 CREBBP DYNC1H1	2.92e-04	513	51	7	int:RPS20
Interaction	CYLD interactions	SLAIN2 UBQLN2 RNF31 TLN1 AMOTL1 UBR4 CLTC GIGYF2 DYNC1H1	2.92e-04	868	51	9	int:CYLD
Interaction	VDR interactions	NCOA2 NCOA6 CREBBP EP300	2.99e-04	127	51	4	int:VDR
Interaction	SNRPB interactions	IGF2BP3 UBQLN2 TLN1 GIGYF2 DIDO1 LSM7 DYNC1H1	3.06e-04	517	51	7	int:SNRPB
Interaction	CDH17 interactions	UBQLN2 PCDH18	3.40e-04	11	51	2	int:CDH17
Interaction	YAP1 interactions	NCOA6 UBQLN2 TLN1 AMOTL1 CLTC GIGYF2 DIDO1 CREBBP EP300 DYNC1H1	3.58e-04	1095	51	10	int:YAP1
Interaction	TLE3 interactions	NCOA2 SPTBN4 ATE1 BCL9 CREBBP EP300	3.59e-04	376	51	6	int:TLE3
Interaction	WDR5 interactions	NCOA6 IGF2BP3 TLN1 UBR4 CLTC GIGYF2 CHD7 CREBBP EP300 DYNC1H1	3.74e-04	1101	51	10	int:WDR5
Interaction	MTNR1B interactions	UBQLN2 TLN1 UBR4 DYNC1H1	3.77e-04	135	51	4	int:MTNR1B
Interaction	BCL3 interactions	GTF2A1 CREBBP EP300	3.85e-04	56	51	3	int:BCL3
Interaction	TPRX2 interactions	NCOA2 NCOA6 CREBBP	3.85e-04	56	51	3	int:TPRX2
Interaction	MEX3A interactions	TLN1 AMOTL1 CLTC CREBBP EP300 DYNC1H1	4.02e-04	384	51	6	int:MEX3A
Interaction	SOX15 interactions	NCOA2 IGF2BP3 BCL9 EP300	4.45e-04	141	51	4	int:SOX15
Interaction	NCOA2 interactions	NCOA2 NCOA6 CREBBP EP300	4.45e-04	141	51	4	int:NCOA2
Interaction	CRX interactions	NCOA2 CHD7 BCL9 CREBBP EP300	4.48e-04	254	51	5	int:CRX
Interaction	ASCL2 interactions	NCOA6 EP300	4.81e-04	13	51	2	int:ASCL2
Interaction	NCOA1 interactions	NCOA2 NCOA6 CREBBP EP300	5.07e-04	146	51	4	int:NCOA1
Interaction	SIRT7 interactions	IGF2BP3 TLN1 UBR4 CLTC GIGYF2 DIDO1 CHD7 DYNC1H1	5.19e-04	744	51	8	int:SIRT7
Interaction	CCT6A interactions	GPC1 UBQLN2 RNF31 CLTC LOXL4 DUX4 EP300	5.49e-04	570	51	7	int:CCT6A
Interaction	ADRM1 interactions	UBQLN2 RNF31 CLTC EP300 DYNC1H1	5.52e-04	266	51	5	int:ADRM1
Interaction	KIF11 interactions	UBQLN2 RNF31 TLN1 BCL9 EP300	5.61e-04	267	51	5	int:KIF11
Interaction	FUS interactions	NCOA6 IGF2BP3 UBQLN2 DIDO1 DUX4 CREBBP EP300 DYNC1H1	5.81e-04	757	51	8	int:FUS
Interaction	PER2 interactions	GTF2A1 TLN1 CLTC ASPM	6.05e-04	153	51	4	int:PER2
Interaction	HNF4A interactions	NCOA2 NCOA6 CHD7 CREBBP EP300	6.42e-04	275	51	5	int:HNF4A
Interaction	KLF2 interactions	CREBBP EP300	6.46e-04	15	51	2	int:KLF2
Interaction	FOCAD interactions	SLAIN2 DIDO1 RNF145	6.53e-04	67	51	3	int:FOCAD
Interaction	NR3C1 interactions	NCOA2 NCOA6 PTPRN2 UBR4 CHD7 BCL9 CREBBP EP300 RYR2	6.76e-04	974	51	9	int:NR3C1
Interaction	GCM1 interactions	BCL9 CREBBP EP300	6.81e-04	68	51	3	int:GCM1
Interaction	PRPF8 interactions	RNF31 UBR4 CLTC GIGYF2 DUX4 LSM7 EP300 DYNC1H1	6.84e-04	776	51	8	int:PRPF8
Interaction	KLF4 interactions	IGF2BP3 BCL9 CREBBP EP300	7.15e-04	160	51	4	int:KLF4
Interaction	RNF181 interactions	UBQLN2 UBR4 RNF145 DYNC1H1	7.15e-04	160	51	4	int:RNF181
Interaction	NPM1 interactions	GPC1 SLAIN2 IGF2BP3 UBQLN2 RNF31 CLTC ASPM DIDO1 DUX4 EP300	7.40e-04	1201	51	10	int:NPM1
Interaction	KLF15 interactions	NCOA2 IGF2BP3 BCL9 CREBBP EP300	8.15e-04	290	51	5	int:KLF15
Interaction	HSPA2 interactions	SCYL2 NCOA2 UBQLN2 TLN1 CLTC LOXL4	8.21e-04	440	51	6	int:HSPA2
Interaction	SNRPC interactions	IGF2BP3 UBQLN2 RNF31 GIGYF2 DIDO1 LSM7	8.21e-04	440	51	6	int:SNRPC
Interaction	TLX3 interactions	NCOA2 NCOA6 CHD7 BCL9 EP300	8.28e-04	291	51	5	int:TLX3
Interaction	KISS1 interactions	UBQLN2 CREBBP	8.33e-04	17	51	2	int:KISS1
Interaction	MAML2 interactions	CREBBP EP300	8.33e-04	17	51	2	int:MAML2
Interaction	FBXO43 interactions	TLN1 CLTC DYNC1H1	8.72e-04	74	51	3	int:FBXO43
Interaction	RXRA interactions	NCOA2 NCOA6 CREBBP EP300	8.77e-04	169	51	4	int:RXRA
Interaction	TGS1 interactions	NCOA6 CREBBP EP300	9.07e-04	75	51	3	int:TGS1
Interaction	CUL9 interactions	SCYL2 PTPRN2 LOXL4 DYNC1H1	9.17e-04	171	51	4	int:CUL9
Interaction	AP2A1 interactions	IGF2BP3 UBQLN2 CLTC DUX4 EP300	9.34e-04	299	51	5	int:AP2A1
Interaction	KLC2 interactions	SLAIN2 CLTC LSM7 EP300	9.37e-04	172	51	4	int:KLC2
Interaction	TACC2 interactions	SLAIN2 CREBBP EP300	9.79e-04	77	51	3	int:TACC2
Interaction	BRCA1 interactions	NCOA2 SLAIN2 IGF2BP3 TLN1 UBR4 CLTC KPNA6 CREBBP EP300 DYNC1H1	1.00e-03	1249	51	10	int:BRCA1
Interaction	SRI interactions	UBQLN2 RYR2 RYR3	1.02e-03	78	51	3	int:SRI
Interaction	NEUROG1 interactions	CREBBP EP300	1.04e-03	19	51	2	int:NEUROG1
Interaction	RBMX interactions	IGF2BP3 UBQLN2 RNF31 CLTC EP300 DYNC1H1	1.04e-03	461	51	6	int:RBMX
Cytoband	4q35.2	DUX4L2 DUX4L5 DUX4L6 DUX4L3 DUX4L7	1.95e-10	27	57	5	4q35.2
Cytoband	Ensembl 112 genes in cytogenetic band chr4q35	DUX4L2 DUX4 DUX4L5 DUX4L6 DUX4L3 DUX4L7	7.85e-09	117	57	6	chr4q35
GeneFamily	PRD class homeoboxes and pseudogenes	DUX4L2 DUX4L5 DUX4L6 DUX4L3 DUX4L7	1.02e-06	92	36	5	521
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	NCOA2 CREBBP EP300	4.84e-06	17	36	3	486
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR2 RYR3	1.15e-05	3	36	2	287
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	CREBBP EP300	5.78e-04	18	36	2	91
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	GPC1 NCOA6 CLTC GIGYF2 BCL9 CREBBP PCDH18	5.28e-05	467	55	7	M1347
Coexpression	GSE8921_UNSTIM_0H_VS_TLR1_2_STIM_MONOCYTE_24H_UP	ADGRB3 SSX5 LSM7 TIAM2 RYR3	6.13e-05	199	55	5	M6410
Coexpression	GSE26488_WT_VS_VP16_TRANSGENIC_HDAC7_KO_DOUBLE_POSITIVE_THYMOCYTE_UP	NCOA2 PTPRN2 BCHE CREBBP RYR3	6.28e-05	200	55	5	M8200
Coexpression	GSE5542_UNTREATED_VS_IFNA_TREATED_EPITHELIAL_CELLS_6H_UP	ERICH3 GLB1L3 TLN1 USP46 RYR2	6.28e-05	200	55	5	M6514
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	GPC1 NCOA6 CLTC GIGYF2 BCL9 CREBBP PCDH18	6.61e-05	484	55	7	MM999
ToppCell	facs-Marrow-KLS-18m-Myeloid-granulocytopoietic_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GPC1 AMOTL1 ASPM LOXL4 USP46	1.83e-06	174	52	5	9d5dcd46cf346c381dea68ada6665f7fb68114a3
ToppCell	facs-Marrow-KLS-18m-Myeloid-granulocytopoietic_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GPC1 AMOTL1 ASPM LOXL4 USP46	1.83e-06	174	52	5	53cec5c666c45278a71c21dd9c62a052a97e0fdf
ToppCell	Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	AMOTL1 ADGRB3 BCHE PCDH18 RYR3	2.22e-06	181	52	5	25915e2500430a902db37d79a749ce2990b69810
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-1\|TCGA-Pancreas / Sample_Type by Project: Shred V9	NCOA2 GTF2A1 GIGYF2 CREBBP EP300	2.54e-06	186	52	5	03db813598b67b1e08f759758a1c2023396921fa
ToppCell	Adult-Mesenchymal-myofibroblast_cell-D175\|Adult / Lineage, Cell type, age group and donor	GPC1 SPTBN4 FSIP2 ADGRB3	3.74e-05	161	52	4	048b7dc00746987a24bf870d4d278c4183eb04a2
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-Degenerative_Endothelial_Cell-Degenerative_Peritubular_Capilary_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DSG3 ADGRB3 BCHE DUX4	3.83e-05	162	52	4	5428c9fdb816f564395ebb4520448e5f3a42b025
ToppCell	E18.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SCYL2 SLAIN2 CLTC RYR3	3.93e-05	163	52	4	d2fcd6f561748f7d29a051c504f016952ba32d0f
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|kidney / Disease (COVID-19 only), tissue and cell type	IGF2BP3 PTPRN2 DUX4 RYR2	3.93e-05	163	52	4	19c28ce16a588a7f4a035c32726f6ccd67702b5b
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SPTBN4 LOXL4 QRICH2 RYR3	4.02e-05	164	52	4	d167c7a987b9b35d1e7725c803df4f9cd5380e47
ToppCell	3'-GW_trimst-1-LargeIntestine-Mesenchymal-myocytic-SMC_(PART1/CAPN3+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PNMA6E TLN1 BCHE PCDH18	5.53e-05	178	52	4	0fb36679cddc9ed8f4b5b34e174d5133c2ea1c76
ToppCell	Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	AMOTL1 ADGRB3 BCHE RYR3	6.83e-05	188	52	4	4d1e5f85342ae550086609d7680e32730b78b5d2
ToppCell	Mesenchymal-airway_smooth_muscle_cell\|World / Lineage, Cell type, age group and donor	AMOTL1 ADGRB3 BCHE RYR3	7.12e-05	190	52	4	645e56b02edc3702c7db917b8ecd5eed0decaf71
ToppCell	Basal_cells-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	GPC1 SLC6A2 DSG3 LOXL4	7.27e-05	191	52	4	a98915bad9a4a61dd4cbca798914849b805f4a19
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	CLTC GIGYF2 BCL9 DYNC1H1	7.56e-05	193	52	4	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
ToppCell	PCW_07-8.5\|World / Celltypes from embryonic and fetal-stage human lung	ASPM CHD7 USP46 PCDH18	7.72e-05	194	52	4	5759c83308df017f1faae248e9b85388e25254f0
ToppCell	Parenchymal-10x5prime-Epithelial-Epi_airway_basal-Basal\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	GPC1 DSG3 GLB1L3 LOXL4	8.03e-05	196	52	4	c5adab88140a465698abcbedc6505a43cae7bfd1
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SPTBN4 PTPRN2 ADGRB3 RYR2	8.03e-05	196	52	4	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	Basal_cells-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	GPC1 DSG3 GLB1L3 LOXL4	8.03e-05	196	52	4	3b66f3a79b3f2ebacb4ad646f179e505ab38d6f0
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_basal-Basal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	GPC1 DSG3 GLB1L3 LOXL4	8.19e-05	197	52	4	1e915957ea6a4550ecb9d6ee4b232aa5800faf20
ToppCell	Parenchymal-10x5prime-Epithelial-Epi_airway_basal\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	GPC1 DSG3 GLB1L3 LOXL4	8.19e-05	197	52	4	de772bd2b4cda843777ac879b1087e6444199dfb
ToppCell	Basal_cells\|World / lung cells shred on cell class, cell subclass, sample id	GPC1 DSG3 GLB1L3 LOXL4	8.19e-05	197	52	4	24360b660000bdfb999d58fbf4e29585a97e1785
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SPTBN4 PTPRN2 ADGRB3 RYR2	8.35e-05	198	52	4	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	5'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	GPC1 ADGRB3 BCHE CHD7	8.35e-05	198	52	4	50dfe6efca76ea9683a19b6bff59cb5030d346f1
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SPTBN4 PTPRN2 ADGRB3 RYR2	8.35e-05	198	52	4	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	5'-GW_trimst-2-SmallIntestine-Neuronal-Glial_immature-Glia_3_(BCAN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	GPC1 ADGRB3 BCHE CHD7	8.51e-05	199	52	4	a816b0eed80530113b7e720bbd2311a544ed8ed1
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_basal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	GPC1 DSG3 GLB1L3 LOXL4	8.68e-05	200	52	4	8827653738a931e4a4545e0c7d75be12bed40740
ToppCell	Biopsy_Other_PF-Epithelial-Basal\|Biopsy_Other_PF / Sample group, Lineage and Cell type	GPC1 DSG3 GLB1L3 LOXL4	8.68e-05	200	52	4	7098ae4b0ea8ba607519eaed8577c577530fc2a1
ToppCell	Bronchial-10x5prime-Epithelial-Epi_airway_basal-Basal\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	GPC1 DSG3 GLB1L3 LOXL4	8.68e-05	200	52	4	0594ca7bc313b73e1dc800cf058f8f798b0284cb
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA	NCOA2 NCOA6 DIDO1 USP46 CREBBP EP300	4.04e-06	172	56	6	1072_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	SCYL2 NCOA2 GIGYF2 DIDO1 CHD7 CREBBP	5.78e-06	183	56	6	7498_DN
Drug	2-hydroxycarbazole	RYR2 RYR3	1.78e-05	3	56	2	CID000093551
Drug	cis-diammineplatinum(II	RYR2 RYR3	1.78e-05	3	56	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR2 RYR3	1.78e-05	3	56	2	CID002750949
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR2 RYR3	1.78e-05	3	56	2	CID005748312
Drug	8N3-cADPR	RYR2 RYR3	1.78e-05	3	56	2	CID000127713
Drug	aminodantrolene	RYR2 RYR3	1.78e-05	3	56	2	CID009570289
Drug	succinylcholine	BCHE CREBBP RYR2 RYR3	1.87e-05	64	56	4	CID000005314
Drug	PCB74	RYR2 RYR3	3.55e-05	4	56	2	CID000036218
Drug	148504-47-6	RYR2 RYR3	3.55e-05	4	56	2	CID006444275
Drug	SC 38249	RYR2 RYR3	3.55e-05	4	56	2	CID000134834
Drug	AC1L1U7A	RYR2 RYR3	3.55e-05	4	56	2	CID000035682
Drug	2,4-xylidinothiazoline	NCOA6 RYR2 RYR3	5.46e-05	30	56	3	CID000099296
Drug	MF101 extract	NCOA2 CREBBP	5.91e-05	5	56	2	ctd:C517398
Drug	3,4-dimethoxy-N-((2,2-dimethyl-2H-chromen-6-yl)methyl)-N-phenylbenzenesulfonamide	CREBBP EP300	5.91e-05	5	56	2	ctd:C575894
Drug	anatoxin-a(s	NCOA6 BCHE	5.91e-05	5	56	2	CID000114989
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	NCOA2 NCOA6 DIDO1 CREBBP EP300	6.14e-05	170	56	5	1050_DN
Drug	SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA	NCOA2 NCOA6 DIDO1 CREBBP EP300	7.05e-05	175	56	5	1058_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	NCOA2 GTF2A1 DIDO1 CREBBP EP300	7.44e-05	177	56	5	3227_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	NCOA2 NCOA6 DIDO1 USP46 CREBBP	7.64e-05	178	56	5	1112_DN
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	NCOA2 DIDO1 USP46 CREBBP EP300	8.05e-05	180	56	5	6886_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	IGF2BP3 GIGYF2 DIDO1 CREBBP EP300	8.05e-05	180	56	5	4541_DN
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A	NCOA2 DIDO1 USP46 CREBBP EP300	8.26e-05	181	56	5	6951_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOA2 ASPM GIGYF2 CHD7 CREBBP	8.48e-05	182	56	5	3887_DN
Drug	MBED	RYR2 RYR3	8.86e-05	6	56	2	CID000129958
Drug	chloro-m-cresol	RYR2 RYR3	8.86e-05	6	56	2	CID000012008
Drug	AC1O528X	RYR2 RYR3	8.86e-05	6	56	2	CID006475857
Drug	AR45	NCOA2 BCHE	8.86e-05	6	56	2	CID000111148
Drug	NSC114784	RYR2 RYR3	8.86e-05	6	56	2	CID000419425
Drug	Azumoleno	RYR2 RYR3	1.24e-04	7	56	2	CID000056259
Drug	Br2BAPTA	RYR2 RYR3	1.24e-04	7	56	2	CID003081001
Drug	trichlorobiphenyl	DSG3 BCHE	1.24e-04	7	56	2	CID000041541
Drug	[[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate	RYR2 RYR3	1.24e-04	7	56	2	CID009547999
Drug	mTST	CLTC BCHE	1.65e-04	8	56	2	CID000069529
Drug	3,3',4',5-tetrachlorosalicylanilide	NCOA6 CLTC	2.12e-04	9	56	2	CID000014385
Drug	isoprocarb	CLTC BCHE	2.12e-04	9	56	2	CID000017517
Drug	FLA 365	LOXL4 RYR3	2.12e-04	9	56	2	CID000072776
Drug	ts M	BCHE RYR2 RYR3	2.25e-04	48	56	3	CID000428025
Disease	Menke-Hennekam syndrome	CREBBP EP300	3.05e-06	2	52	2	cv:C5681632
Disease	Rubinstein-Taybi syndrome (implicated_via_orthology)	CREBBP EP300	3.05e-06	2	52	2	DOID:1933 (implicated_via_orthology)
Disease	Rubinstein-Taybi syndrome	CREBBP EP300	3.05e-06	2	52	2	cv:C0035934
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	3.05e-06	2	52	2	C4551859
Disease	RUBINSTEIN-TAYBI SYNDROME 1	CREBBP EP300	3.05e-06	2	52	2	180849
Disease	Rubinstein-Taybi syndrome due to CREBBP mutations	CREBBP EP300	3.05e-06	2	52	2	cv:C4551859
Disease	Rubinstein-Taybi syndrome (is_implicated_in)	CREBBP EP300	3.05e-06	2	52	2	DOID:1933 (is_implicated_in)
Disease	Rubinstein-Taybi Syndrome	CREBBP EP300	3.05e-06	2	52	2	C0035934
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR2 RYR3	9.13e-06	3	52	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR2 RYR3	9.13e-06	3	52	2	DOID:8545 (implicated_via_orthology)
Disease	Bladder Neoplasm	NCAN LOXL4 CREBBP EP300	1.10e-04	140	52	4	C0005695
Disease	Malignant neoplasm of urinary bladder	NCAN LOXL4 CREBBP EP300	1.13e-04	141	52	4	C0005684
Disease	Diffuse Large B-Cell Lymphoma	CLTC CREBBP EP300	1.27e-04	55	52	3	C0079744
Disease	Cleft palate, cleft lip	GPC1 PTPRN2 ADGRB3 GIGYF2 CREBBP	1.32e-04	279	52	5	EFO_0003959, HP_0000175
Disease	autism spectrum disorder (implicated_via_orthology)	SLC6A2 NEXMIF CHD7 CREBBP	1.51e-04	152	52	4	DOID:0060041 (implicated_via_orthology)
Disease	Precursor Cell Lymphoblastic Leukemia Lymphoma	DUX4 CREBBP EP300	1.73e-04	61	52	3	C1961102
Disease	salicylurate measurement	SLAIN2 RYR2	2.35e-04	13	52	2	EFO_0010532
Disease	alcohol use disorder (implicated_via_orthology)	CREBBP EP300 RYR2 RYR3	3.91e-04	195	52	4	DOID:1574 (implicated_via_orthology)
Disease	forced expiratory volume	NCOA6 IGF2BP3 ZFP57 BCHE ATE1 BCL9 RYR2	4.47e-04	789	52	7	EFO_0004314
Disease	Tachyarrhythmia	BCHE RYR2	4.58e-04	18	52	2	C0080203
Disease	Tachycardia	BCHE RYR2	4.58e-04	18	52	2	C0039231
Disease	Malignant neoplasm of breast	GPC1 NCOA2 GTF2A1 NCOA6 ALKBH8 UBR4 BCHE EP300	5.45e-04	1074	52	8	C0006142
Disease	Squamous cell carcinoma of esophagus	DIDO1 CREBBP EP300	6.37e-04	95	52	3	C0279626
Disease	Adenoid Cystic Carcinoma	ASPM CREBBP EP300	7.40e-04	100	52	3	C0010606
Disease	urate measurement, bone density	SCYL2 SLC6A2 FSIP2 PTPRN2 ADGRB3 TIAM2	7.46e-04	619	52	6	EFO_0003923, EFO_0004531
Disease	Seizures, Focal	SLC6A2 BCHE DYNC1H1	8.29e-04	104	52	3	C0751495
Disease	Bipolar Disorder	SLC6A2 NCAN BCHE USP46 BCL9	1.50e-03	477	52	5	C0005586
Disease	systolic blood pressure, body mass index	ADGRB3 BCL9	1.65e-03	34	52	2	EFO_0004340, EFO_0006335

Protein segments in the cluster

Peptide	Gene	Start	Entry
EGQADVQMNGIPQSP	ERICH3	516	Q5RHP9
MQAGVQRAGLPQQQP	EP300	2136	Q09472
IGPGMANHNQFQQPQ	EP300	2201	Q09472
GNPEAPGNMGLFDQQ	BCHE	186	P06276
NPEFNMNPPVMDQFN	ADGRB3	1346	O60242
PDQMTINQYEPGQGI	ALKBH8	221	Q96BT7
PQQQAMGGLNPQGQA	CREBBP	2156	Q92793
TQQKHGNGQPANMPE	AMOTL1	646	Q8IY63
QGQMQGIPAPSQALQ	DUX4L6	346	P0CJ89
ECGYPENPVNPMGQQ	CHD7	26	Q9P2D1
ENLAMNEGGPPTENN	ASPM	196	Q8IZT6
VQPGIGQQGMVQPQA	QRICH2	746	Q9H0J4
GELQNQMPGPSKEEQ	PTPRN2	471	Q92932
NMFIPGEEFPTQPQQ	PCDH18	946	Q9HCL0
NDNPPVFSQQIFMGE	DSG3	151	P32926
QFIFQQPEAPMEGFQ	KPNA6	521	O60684
NVPNMGFQNQVRLAG	LOXL4	411	Q96JB6
QGQMQGIPAPSQALQ	DUX4	346	Q9UBX2
PEVMGDGLANQINNP	GPC1	426	P35052
PVNMENLPINNGSGQ	GLB1L3	436	Q8NCI6
NFNGMPHNVDEPTPQ	FSIP2	1806	Q5CZC0
QGQMQGIPAPSQALQ	DUX4L3	346	P0CJ86
EFQDMPSFPAQPQGQ	PNMA6E	101	A0A0J9YXQ4
DEMAAQQNPLQQPRG	IGF2BP3	156	O00425
AGQANPNFMQGQVPS	NCOA6	521	Q14686
PQGEIQGPFNNQEMA	GIGYF2	541	Q6Y7W6
GNMDRNPNNDQVFPN	FCGBP	1816	Q9Y6R7
FPNPQGLSEEMFQQQ	BCL9	621	O00512
MPGPRGIQPQQFEDQ	DIDO1	1956	Q9BTC0
QGQMQGIPAPSQALQ	DUX4L7	346	P0CJ90
PQDGMEAIPNPFIQQ	LSM7	86	Q9UK45
MQQNPAGELEGFQAQ	ATE1	221	O95260
VAQQNQGEVPEPQDM	DYNC1H1	491	Q14204
NVQMNAQGGPVLNEE	HERPUD2	256	Q9BSE4
QGQMQGIPAPSQALQ	DUX4L5	346	P0CJ88
NGQPVQGMFENFNID	RYR2	771	Q92736
MNPQVQPENNGADTG	SLC6A2	6	P23975
QQQFDEFCKQMQPPG	SVBP	51	Q8N300
NFQVPNGGIPRMQPQ	SLAIN2	436	Q9P270
NGEICFPFQQGPVNM	NEXMIF	971	Q5QGS0
FQQQEPEPGLQGGME	NCAN	491	O14594
MQGNPFFNPQNFAQP	SCYL2	896	Q6P3W7
PDQGQQFAQMLVQDE	CLTC	526	Q00610
EPQNFPNSGMQRAVQ	C12orf50	296	Q8NA57
SNINFPINGPKEQMG	NCOA2	421	Q15596
LQDNNVMFNTEPPAG	RNF31	946	Q96EP0
QMQPGGVQAPVIQQV	GTF2A1	191	P52655
QEPIFRTEGPMAQNQ	ZFP57	246	Q9NU63
SQANGMEGPRENQDP	TIAM2	1071	Q8IVF5
RINGQPVQGMFENFN	RYR3	756	Q15413
ENFQVGSMPPAQQQI	TLN1	461	Q9Y490
NDPNRGNQVEHPQMT	SSX5	86	O60225
GEVDNMEGLPAPNNN	SPTBN4	6	Q9H254
NGNMNEPAENNKPEL	USP46	151	P62068
QEPMLNAAQEQFGGN	UBQLN2	276	Q9UHD9
DPQQEDFLQGRMPGN	UBR4	4356	Q5T4S7
QNVMFQEGTEPPGQE	RNF145	601	Q96MT1
QGQMQGIPAPSQALQ	DUX4L2	346	P0CJ85